What a difference a decade makes. I left the Boston/Cambridge biotech community in 2005, when it was a lot sleepier and a lot smaller. Focused densely within just a few dozen... Read more »
[Editor’s note: As a New Year’s exercise, we asked a select group of Xconomists to answer this question: “What’s the craziest idea out there that just might succeed?”]
Drugs for type... Read more »
[Editor’s note: We asked a group of Xconomists to answer the following question: “If you could patent one thing, what would it be?”]
A DNA sequencing technology that results in full... Read more »
1. FDA’s decision to remove the breast cancer indication from the label of bevacizumab (Avastin).
2. Approval of Dendreon’s sipuleucel-T (Provenge), representing a new class of drug.
3. Sanofi-Aventis’ pursuit of... Read more »